Skip to content
Boca Raton City Online – Lifestyle
Author:
Biomea Fusion, Inc.
Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity
August 13, 2026
Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights
August 5, 2026
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study
June 5, 2026
Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity
June 3, 2026
Biomea Fusion to Participate at Upcoming Investor Conferences
May 12, 2026
Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies
March 31, 2026
Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights
March 24, 2026
Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026
March 14, 2026
Biomea Fusion to Participate at Upcoming Investor Conferences
March 7, 2026